Risk Factors for Development of HCC in Chronic HBV Infection Risk Factors for Development of HCC in Chronic HBV Infection
How do various metabolic factors and comorbidities influence hepatocellular carcinoma risk in patients with chronic hepatitis B infection?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 4, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
New combination therapy offers chance of healing hepatitis B
(German Center for Infection Research) Around 260 million people, more than three percent of the global population, are chronically infected with the hepatitis B virus (HBV); in the long term, this often leads to complications such as liver cirrhosis and liver cancer. A cure is not yet possible with the available medication. Scientists at the German Center for Infection Research (DZIF) and the University Hospital Eppendorf (UKE) have now investigated a new combination therapy that has proven highly effective in their infection model. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 4, 2021 Category: Infectious Diseases Source Type: news
New biosensors quickly detect coronavirus proteins and antibodies
(University of Washington Health Sciences/UW Medicine) Researchers have designed protein-based biosensors that glow when mixed with targeted molecules, such as components of the pandemic coronavirus or specific COVID-19 antibodies. This development could allow for faster, more widespread testing in the near future. Similar biosensors could be designed to detect medically relevant human proteins such as Her2 (a biomarker for some breast cancers) and Bcl-2 (which has clinical significance in some other cancers), as well as a bacterial toxin and antibodies that target Hepatitis B virus. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 28, 2021 Category: Cancer & Oncology Source Type: news
Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV
TITUSVILLE, N.J., January 21, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen’s 25-year commitment to make HIV history. In the U.S., ViiV Healthcare is the marketing authorization holder for CABENUVA.C...
Source: Johnson and Johnson - January 22, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
mRNA Technology Gave Us the First COVID-19 Vaccines. It Could Also Upend the Drug Industry
“No!” The doctor snapped. “Look at me!”
I had been staring her in the eyes, as she had ordered, but when a doctor on my other side began jabbing me with a needle, I started to turn my head. “Don’t look at it,” the first doctor said. I obeyed.
This was in early August in New Orleans, where I had signed up to be a participant in the clinical trial for the Pfizer-BioNTech COVID-19 vaccine. It was a blind study, which meant I was not supposed to know whether I had gotten the placebo or the real vaccine. I asked the doctor if I would really been able to tell by looking at the syringe. &...
Source: TIME: Health - January 11, 2021 Category: Consumer Health News Authors: Walter Isaacson Tags: Uncategorized COVID-19 feature Magazine Source Type: news
mRNA Technology Gave Us the First COVID-19 Vaccines. It Could Also Upend the Drug Industry
“No!” The doctor snapped. “Look at me!”
I had been staring her in the eyes, as she had ordered, but when a doctor on my other side began jabbing me with a needle, I started to turn my head. “Don’t look at it,” the first doctor said. I obeyed.
This was in early August in New Orleans, where I had signed up to be a participant in the clinical trial for the Pfizer-BioNTech COVID-19 vaccine. It was a blind study, which meant I was not supposed to know whether I had gotten the placebo or the real vaccine. I asked the doctor if I would really been able to tell by looking at the syringe. &...
Source: TIME: Science - January 11, 2021 Category: Science Authors: Walter Isaacson Tags: Uncategorized COVID-19 feature Magazine Source Type: news
New viral detection technique uses smartphone camera to diagnose various infections
(American Association for the Advancement of Science) Scientists have developed a novel smartphone-based technique to diagnose viral infections that uses a deep learning algorithm to identify viruses in metal nanoparticle-labeled samples, enabling rapid virus detection without the need for skilled laboratory workers and expensive equipment. The system correctly identified clinically relevant concentrations of Zika, hepatitis B (HBV), or hepatitis C (HCV) in 134 patient samples with 98.97% sensitivity. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 16, 2020 Category: Infectious Diseases Source Type: news
USPSTF Recommends Hep B Screen for At-Risk Teens, Adults
TUESDAY, Dec. 15, 2020 -- The U.S. Preventive Services Task Force (USPSTF) concludes that screening adults and adolescents at increased risk for hepatitis B virus (HBV) infection has moderate net benefit. These findings form the basis of a final... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 15, 2020 Category: Pharmaceuticals Source Type: news
USPSTF statement on screening for hepatitis B virus infection in adolescents, adults
(JAMA Network) The US Preventive Services Task Force (USPSTF) recommends screening for hepatitis B virus infection in adolescents and adults at increased risk for infection. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 15, 2020 Category: Infectious Diseases Source Type: news
The Ambulance Science Podcast: Make Up Your Own Mind About the Vaccine
Get every episode of The Ambulance Science Podcast by subscribing to Apple Podcasts or Google Podcasts.
Where I’m coming from (compared to most of my colleagues):
Master’s in Public Health with a concentration in Health Policy from Yale Medical School.FT Faculty at GWU School of Medicine & Southern Connecticut State University MPH Program, and long-time adjunct faculty at NYMC MPH program in Health Policy.Assistant Commissioner of Health at the NYC Department of Health & Mental Hygiene during the first SARS outbreak.Served as State EMS Director, Consultant to Public Health ...
Source: JEMS Special Topics - December 14, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Podcasts Ambulance Science Source Type: news
Aspirin and Statins in Chronic Hepatitis B: It's Complicated Aspirin and Statins in Chronic Hepatitis B: It's Complicated
Statins play a bigger part than aspirin in reducing risk for hepatocellular carcinoma in patients with hepatitis B, new research shows, and cirrhosis seems to cancel any beneficial effect of aspirin.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 19, 2020 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
Mixed Outcomes in Tenofovir Trial for Chronic Hepatitis B Mixed Outcomes in Tenofovir Trial for Chronic Hepatitis B
Levels of surface antigen loss were low whether or not patients treated with tenofovir also received interferon, but some patients met criteria for inactive chronic disease after therapy withdrawal.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 15, 2020 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
Researchers discover enzyme suppressing immune response to viral infections
(University of Missouri-Columbia) Viruses such as HIV, hepatitis B and hepatitis C evade or disrupt the immune system to create persistent infections. These viruses remain a serious health threat, but researchers from the University of Missouri School of Medicine have discovered how an enzyme that regulates several cellular processes might be a key target to preventing viruses from disarming the human immune response. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 10, 2020 Category: Cancer & Oncology Source Type: news
Sexually transmitted infections in women deprived of liberty in Roraima, Brazil - Benedetti MSG, Nogami ASA, Costa BB, Fons êca HIF, Costa IDS, Almeida IS, Miranda L, Conchy MMM, Bentes RS, Higa SN, Israel TS, Fonseca AJ.
OBJECTIVE: To evaluate the prevalence of HIV, syphilis and hepatitis B infection among women deprived of liberty in the state of Roraima, Brazil, and its correlation with perceptions, knowledge and behavioral factors.
METHOD: This is a cross-sectional ... (Source: SafetyLit)
Source: SafetyLit - November 7, 2020 Category: International Medicine & Public Health Tags: Risk Factor Prevalence, Injury Occurrence Source Type: news
European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of...
Source: Roche Media News - November 2, 2020 Category: Pharmaceuticals Source Type: news
